Meropenem is the second generation carbapenem antibiotics

with broad spectrum and potent antibacterial activity

and is the first-line treatment for severe infection in clinic. Meropenem is widely distributed in tissues and body fluids

and is excreted through the kidneys

with a short elimination half-life（ T1/2 approximately1 h）. Therefore

when patients have significant changes in apparent volume of distribution or renal function

the pharmacokinetic parameters of meropenem will be significantly affected. Meropenem is a kind of time-dependent antibacterial drugs

and its blood concentration must be higher than the minimum inhibitory concentration of pathogenic bacteria and maintained for a certain period of time in order to play a bactericidal role. At present

a variety of methods have been established for the determination of the blood concentration of meropenem. It is necessary to monitor the blood concentration of patients with severe clinical infections or with renal impairment or renal replacement therapy

and to formulate and modify the dosing regimen based on the sensitivity of pathogenic bacteria to obtain a higher clinical cure rate and reduce the occurrence of bacterial resistance.